Earnings
|
Reports Q revenue… Reports Q revenue $137.9M, consensus $129.26M.Net income was $3.2M for the fourth quarter of 2022, as compared to a loss of $2.4M in the corresponding prior year period. The diluted income per share for the fourth quarter of 2022 was $ 10c, as compared to the diluted loss per share of 9c in the prior year period. "We are pleased with our strong performance in the fourth quarter and full year 2022. Our growth in the fourth quarter, as well as for the year, was primarily driven by higher utilization at existing centers and the addition of 61 newU.S. implanting centers and 16 new U.S. sales territories. With significant momentum and many accomplishments throughout our business, we are proud to achieve our first profitable quarter," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "Given our strong performance in 2022, we are providing 2023 revenue guidance of between $560 million to $570 million, an increase of 37% to 40% year-over-year.""We completed several important milestones in 2022 including an expanded label for full-body MRI compatibility, the commercial launches of our Bluetooth(R)-enabled patient remote and our silicone-based stimulation and sensing leads, the FDA submission of our SleepSync programmer, and important indication expansions for Pediatric Down Syndrome and higher AHI and BMI. We completed enrollment of 300 patients in our PREDICTOR study which aims to remove the drug-induced sleep endoscopy requirement for most patients with BMI under 32. We also made strategic investments in EnsoData and Ognomy and initiated a pilot of a digital scheduling tool to facilitate and streamline patient access to care through our Advisor Care Program," concluded Mr. Herbert. ShowHide Related Items >><< - 12/20/22
- Inspire Medical publishes inaugural ESG summary report
- 09/14/22
- Inspire Medical announces updates from ISSS, AAO-HNSF meetings
- 08/15/22
- Inspire Medical appoints Ezgi Yagci as VP, investor relations
- 01/31/23 Truist
- Inspire Medical price target raised to $310 from $308 at Truist
- 01/31/23 Lake Street
- CVRx initiated with a Buy at Lake Street
- 01/26/23 Piper Sandler
- Inspire Medical price target raised to $300 from $285 at Piper Sandler
- 12/13/22 Goldman Sachs
- Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
- 01/09/23
- Inspire Medical sees FY22 revenue $407.5M-$407.9M, consensus $387.61M
- 01/09/23
- Inspire Medical sees Q4 revenue $137.5M-$137.9M, consensus $117.03M
- 11/01/22
- Inspire Medical raises FY22 revenue view to $384M-$388M from $354M-$362M
- 11/01/22
- Inspire Medical reports Q3 EPS (60c), consensus (77c)
|
On The Fly
| ShowHide Related Items >><< - 11/02/22
- Xometry CEO sells $1.2M in common stock
- 10/05/22
- Xometry CEO sells $1.17M in common stock
- 10/03/22
- Xometry appoints Matt Leibel as CTO, Brendan Sterne as CPO
- 08/25/22
- Xometry, CCBC announce public-private partnership for two-year scholarships
- 01/24/23
- Truist Financial trading resumes
- 01/24/23
- Truist Financial trading halted, volatility trading pause
- 12/14/22
- Truist Financial raises prime rate to 7.5% from 7%
- 11/28/22
- Main Street announces new $240M secured credit facility
- 01/23/23
- Association of Pickleball Professionals announces broadcast deals with CBS, ESPN
- 12/08/22
- Paramount+ launches in Germany, Switzerland and Austria
- 12/07/22
- Paramount CEO says view of 2023 as peak streaming investment year hasn't changed
- 12/06/22
- Paramount CEO sees Q4 ad business 'a bit below' Q3
- 11/28/22
- PBF Energy to replace Nu Skin in the S&P 400 at open on 12/1
- 01/25/23
- New Fortress Energy unit wins contract to manage Puerto Rico power plants
- 01/03/23
- Director of New Fortress Energy Wilkinson sells $454,348 in company shares
- 11/22/22
- New Fortress Energy finalizes agreements with Pemex
- 10/28/22
- New Fortress Energy finalizes agreement with Comision Federal de Electricidad
- $148.95 /
+1.905 (+1.30%) - 01/30/23
- Instagram launches Notes in Europe and Japan
- 01/26/23
- Privacy chief of Canada: Home Depot shared personal customer data with Meta
- 01/25/23
- Meta ends suspension of Trump's Facebook, Instagram accounts
- 01/23/23
- Meta expands partnership with NBA, WNBA as league's official VR headset
- 01/30/23
- Medtronic recalls Hemodialysis Catheters for leaks, FDA says
- 01/27/23
- Orchestra BioMed begins trading on Nasdaq with cash runway into 2026
- 01/25/23
- Medtronic recommends rejection of below-market mini-tender by TRC Capital
- 01/09/23
- Medtronic sees getting back to pre-Covid gross margin levels in 3-4 years
- 11/18/22
- LyondellBasell moving forward with advanced recylicng plant in Germany
- 11/17/22
- LyondellBasell evaluates propylene expansion project
- 10/20/22
- LyondellBasell, Shakti Plastic sign MoU to operate recycling plant in India
- 10/19/22
- Air Liquide, Chevron, others team team on hydrogen project along US Gulf Coast
- 01/18/23
- Inter&Co announces '60-30-30' long-term growth targets
- 11/29/22
- Inter&Co joins Amazon's Payment Service Provider Program
- 09/16/22
- Inter&Co rebrands its remittances business in U.S.
- 12/20/22
- Inspire Medical publishes inaugural ESG summary report
- 09/14/22
- Inspire Medical announces updates from ISSS, AAO-HNSF meetings
- 08/15/22
- Inspire Medical appoints Ezgi Yagci as VP, investor relations
- 08/01/22
- Inspire Medical appoints Cynthia Burks, Charisse Sparks to board
- 12/11/22
- Incyte's novel mutant CALR antibody unveiled at ASH 2022
- 12/05/22
- Syndax, Incyte report axatilimab Phase 1/2 data
- 12/02/22
- Incyte, CMS Aesthetics enter ruxolitinib collaboration and license agreement
- 11/07/22
- Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact
- 01/24/23
- Irenic Capital comments on withdrawal of proposal to combine News Corp, Fox
- 01/24/23
- Rupert Murdoch withdrawing proposal for Fox Corp, News Corp. combination
- 01/24/23
- Rupert Murdoch withdraws proposal for Fox News, News Corp. tie-up
- 01/24/23
- Rupert Murdoch withdrawing proposal for Fox Corp, News Corp. combination
- 10/20/22
- FleetCor to acquire European workforce lodging provider Roomex
- 09/26/22
- FleetCor CFO Freund to leave company
- 09/07/22
- FleetCor signs network agreements with Exxon Mobil
- 09/06/22
- FleetCor acquires Plugsurfing, terms not stated
- 08/26/22
- FibroGen announces completion of patient enrollment in MATTERHORN
- 12/08/22
- Edwards Lifesciences CEO Michael Mussallem to retire, Bernard Zovighian succeeds
- 11/01/22
- Edwards Lifesciences authorizes $750M accelerated share repurchase
- 10/28/22
- Edwards Lifesciences falls -16.6%
- 10/28/22
- Edwards Lifesciences falls -14.3%
- 11/03/22
- CVRx announces launch of Barostim NEO2 IPG
- 01/13/23
- Bank of America sees mid-single digit loan growth next year
- 01/13/23
- Bank of America sees Q1 NII around $14.4B
- 01/13/23
- Bank of America sees net charge-offs moving to pre-pandemic levels
- 01/13/23
- Bank of America starting to see stabilization in deposits, says CEO
- 01/31/23 BofA
- FleetCor upgraded to Buy at BofA as risks get addressed 'head on'
- 01/31/23 BofA
- FleetCor upgraded to Buy from Neutral at BofA
- 01/25/23 Baird
- FleetCor price target raised to $230 from $220 at Baird
- 01/20/23 Truist
- Wex price target raised to $190 from $170 at Truist
- 01/30/23 William Blair
- FibroGen upgraded to Outperform at William Blair on pamrevlumab's potential
- 01/30/23 William Blair
- FibroGen upgraded to Outperform from Market Perform at William Blair
- 01/26/23 Raymond James
- FibroGen upgraded to Outperform from Market Perform at Raymond James
- 01/26/23 Raymond James
- FibroGen upgraded to Outperform from Market Perform at Raymond James
- 01/31/23 Atlantic Equities
- LyondellBasell upgraded to Overweight from Neutral at Atlantic Equities
- 01/17/23 Fermium Research
- LyondellBasell downgraded to Hold from Buy at Fermium Research
- 01/17/23 Fermium Research
- Dow Inc. downgraded to Hold from Buy at Fermium Research
- 01/12/23 KeyBanc
- LyondellBasell price target raised to $83 from $65 at KeyBanc
- 01/31/23 BTIG
- New Fortress Energy upgraded to Buy from Neutral at BTIG
- 11/16/22 Barclays
- New Fortress Energy price target raised to $53 from $48 at Barclays
- 10/19/22 Jefferies
- New Fortress Energy initiated with a Buy at Jefferies
- 10/19/22 Barclays
- New Fortress Energy price target lowered to $48 from $54 at Barclays
- 01/31/23 Goldman Sachs
- Inter&Co upgraded to Buy from Neutral at Goldman Sachs
- 12/08/22 Grupo Santander
- Inter&Co downgraded to Neutral from Outperform at Grupo Santander
- 09/06/22 Goldman Sachs
- Inter&Co upgraded to Neutral from Sell at Goldman Sachs
- 07/06/22 New Street
- Inter&Co initiated with a Neutral at New Street after listing moved to U.S.
- 01/31/23 Macquarie
- Paramount downgraded to Underperform at Macquarie on high ad exposure
- 01/31/23 Macquarie
- Paramount downgraded to Underperform from Neutral at Macquarie
- 01/12/23 Guggenheim
- Paramount price target raised to $22 from $20 at Guggenheim
- 01/04/23 Macquarie
- Paramount price target lowered to $15 from $16 at Macquarie
- 01/31/23 Bernstein
- Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
- 01/30/23 Piper Sandler
- Edwards Lifesciences downgraded to Neutral from Overweight at Piper Sandler
- 12/12/22 Canaccord
- Edwards Lifesciences price target lowered to $73 from $78 at Canaccord
- 12/12/22 Citi
- Edwards Lifesciences price target lowered to $92 from $99 at Citi
- 01/24/23 Mizuho
- Medtronic price target lowered to $95 from $100 at Mizuho
- 01/09/23 RBC Capital
- Medtronic downgraded to Sector Perform from Outperform at RBC Capital
- 11/30/22 Wells Fargo
- Medtronic price target lowered to $77 from $82 at Wells Fargo
- 01/31/23 Atlantic Equities
- Bank of America downgraded to Neutral from Overweight at Atlantic Equities
- 01/24/23 BofA
- Banks' potential new online wallet unlikely to threaten PayPal, says BofA
- 01/17/23 Citi
- Bank of America price target raised to $38 from $36 at Citi
- 01/17/23 Piper Sandler
- Bank of America downgraded to Underweight from Neutral at Piper Sandler
- 01/31/23 Stephens
- Truist Financial downgraded to Equal Weight at Stephens following outperformance
- 01/31/23 Stephens
- Truist Financial downgraded to Equal Weight from Overweight at Stephens
- 01/09/23 Jefferies
- Truist Financial upgraded to Buy from Hold at Jefferies
- 01/06/23 Deutsche Bank
- Truist downgraded to Hold with $48 target at Deutsche Bank
- 01/31/23 Jefferies
- Nu Skin downgraded to Hold at Jefferies on China execution uncertainty
- 01/30/23 Jefferies
- Nu Skin downgraded to Hold from Buy at Jefferies
- 12/20/22 DA Davidson
- Nu Skin price target raised to $40 from $34 at DA Davidson
- 11/23/22 DA Davidson
- Nu Skin price target lowered to $34 from $40 at DA Davidson
- $148.95 /
+1.905 (+1.30%) - 01/31/23 LightShed Partners
- Meta Platforms initiated with a Buy at LightShed Partners
- 01/30/23 DA Davidson
- DA Davidson neutral on Pinterest ahead of earnings
- 01/27/23 BofA
- BuzzFeed still a 'show me story,' Meta deal not new, says BofA
- 01/26/23 Piper Sandler
- Meta Platforms price target raised to $136 from $116 at Piper Sandler
- 01/31/23 Piper Sandler
- Incyte initiated with an Overweight at Piper Sandler
- 10/24/22 JPMorgan
- Incyte price target lowered to $80 from $86 at JPMorgan
- 08/03/22 Evercore ISI
- Incyte downgraded to In Line from Outperform at Evercore ISI
- 08/03/22 Guggenheim
- Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss
- 01/31/23 Morgan Stanley
- Fox Corp. resumed with an Equal Weight at Morgan Stanley
- 01/25/23 Loop Capital
- Fox upgraded to Buy with $40 price target at Loop Capital
- 01/25/23 Loop Capital
- Loop upgrades News Corp. to Buy on ending of Fox tie-up
- 01/25/23 Loop Capital
- Fox Corp. upgraded to Buy from Hold at Loop Capital
- 01/31/23 Craig-Hallum
- Xometry initiated with a Buy at Craig-Hallum
- 12/14/22 Lake Street
- Xometry initiated with a Sell at Lake Street
- 12/13/22 Citi
- Xometry initiated with a Buy at Citi
- 11/11/22 UBS
- Xometry price target lowered to $45 from $55 at UBS
- 01/31/23 Lake Street
- CVRx initiated with a Buy at Lake Street
- 01/27/23 Canaccord
- CVRx price target lowered to $22 from $23 at Canaccord
- 01/09/23 Piper Sandler
- CVRx price target raised to $18.50 from $14 at Piper Sandler
- 11/02/22 Piper Sandler
- CVRx price target raised to $14 from $10 at Piper Sandler
- 01/31/23 Truist
- Inspire Medical price target raised to $310 from $308 at Truist
- 01/26/23 Piper Sandler
- Inspire Medical price target raised to $300 from $285 at Piper Sandler
- 12/13/22 Goldman Sachs
- Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
- 11/10/22
- Xometry sees Q4 revenue $104M-$106M, consensus $116.11M
- 11/10/22
- Xometry reports Q3 adjusted EPS (11c), consensus (22c)
- 08/10/22
- Xometry sees 2022 revenue $395M-$400M, consensus $397.09M
- 08/10/22
- Xometry sees Q3 revenue $102M-$104M, consensus $103.9M
- 01/19/23
- Truist Financial reports Q4 adjusted EPS $1.30, consensus $1.28
- 01/18/23
- Notable companies reporting before tomorrow's open
- 10/18/22
- Truist Financial reports Q3 adjusted EPS $1.24, consensus $1.24
- 11/02/22
- Paramount reports Q3 adjusted EPS 39c, consensus 43c
- 11/01/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Paramount reports Q2 EPS 53c, consensus 62c
- 11/02/22
- Nu Skin sees 2022 EPS $2.40-$2.60, consensus $3.34
- 11/02/22
- Nu Skin sees Q4 non-GAAP EPS 40c-60c, consensus $1.09
- 11/02/22
- Nu Skin reports Q3 adjusted EPS 47c, consensus 78c
- 11/02/22
- Nu Skin reports Q3 adjusted EPS 47c, consensus 78c
- 11/08/22
- New Fortress Energy reports Q3 EPS 41c, consensus 80c
- 08/04/22
- New Fortress Energy reports Q2 adjusted EPS 69c, consensus 50c
- $148.95 /
+1.905 (+1.30%) - 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 10/26/22
- Meta Platforms sees Q4 revenue $30B-$32.5B, consensus $32.31B
- 10/26/22
- Meta Platforms reports Q3 EPS $1.64, consensus $1.89
- 10/26/22
- Notable companies reporting after market close
- 11/22/22
- Medtronic sees Q3 adjusted EPS $1.25-$1.27, consensus $1.40
- 11/22/22
- Medtronic says guidance assumes 2H23 reported revenue $15.4B-$15.6B
- 11/22/22
- Medtronic cuts FY23 EPS view to $5.25-$5.30 from $5.53-$5.65, consensus $5.53
- 11/22/22
- Medtronic reports Q2 EPS $1.30, consensus $1.28
- 10/28/22
- LyondellBasell reports Q3 adjusted EPS $1.96, consensus $2.84
- 01/09/23
- Inspire Medical sees FY22 revenue $407.5M-$407.9M, consensus $387.61M
- 01/09/23
- Inspire Medical sees Q4 revenue $137.5M-$137.9M, consensus $117.03M
- 11/01/22
- Inspire Medical raises FY22 revenue view to $384M-$388M from $354M-$362M
- 11/01/22
- Inspire Medical reports Q3 EPS (60c), consensus (77c)
- 11/01/22
- Incyte reports Q3 EPS 60c, consensus 72c
- 08/02/22
- Incyte reports Q2 EPS $1.01, consensus 76c
- 11/01/22
- Fox Corp. reports Q1 adjusted EPS $1.21, consensus $1.14
- 10/31/22
- Notable companies reporting before tomorrow's open
- 08/10/22
- Fox Corp. reports Q4 adjusted EPS 74c, consensus 76c
- 11/02/22
- FleetCor reaffirms FY22 adjusted EPS view $15.85-$16.05, consensus $15.97
- 11/02/22
- FleetCor reports Q3 adjusted EPS $4.24 consensus $4.18
- 09/26/22
- FleetCor sees Q3 results at least in line with previously provided outlook
- 08/03/22
- FleetCor raises FY22 adjusted EPS view to $15.85-$16.05, consensus $15.51
- 11/07/22
- FibroGen reports Q3 EPS (98c), consensus (81c)
- 08/08/22
- FibroGen reports Q2 EPS (78c), consensus (94c)
- 01/10/23
- Edwards Lifesciences not reaffirming Q4, 2023 guidance
- 12/08/22
- Edwards Lifesciences backs FY22 adjusted EPS view $2.40-$2.50, consensus $2.46
- 12/08/22
- Edwards Lifesciences sees FY23 adjusted EPS $2.45-$2.60, consensus $2.53
- 10/27/22
- Edwards Lifesciences sees FY22 adjusted EPS $2.40-$2.50, consensus $2.51
- 01/26/23
- CVRx sees FY23 revenue $35M-$38M, consensus $37.03M
- 01/26/23
- CVRx sees Q1 revenue $7.1M-$7.5M, consensus $7.42M
- 01/26/23
- CVRx reports Q4 EPS (51c), consensus (56c)
- 01/09/23
- CVRx sees FY23 revenue $35M-$38M, consensus $38M
- 01/13/23
- Bank of America reports Q4 EPS 85c, consensus 77c
- 01/12/23
- Notable companies reporting before tomorrow's open
- 10/17/22
- Bank of America reports Q3 EPS 81c, consensus 77c
|